Genetics in the pathogenesis of esophageal cancer: Possible predictive and prognostic factors

Journal of Gastrointestinal Surgery

Volumn 14, Issue SUPPL.1, 2010, Pages

  Vallböhmer, Daniel ^a   Brabender, Jan ^a   Metzger, Ralf ^a   Hölscher, Arnulf H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Esophageal adenocarcinoma; Neoadjuvant therapy; Predictive prognostic molecular markers

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; CANCER INVASION; ESOPHAGUS TUMOR; GENETICS; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PROGNOSIS;

ADENOCARCINOMA; APOPTOSIS; ESOPHAGEAL NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77951213046     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-009-1021-5     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66. doi: 10. 3322/canjclin. 57. 1. 43.
2. Wei JT, Shaheen N. The changing epidemiology of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003; 14: 112-127.
3. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97: 142-146.
4. Ando N, Ozawa S, Kitagawa Y et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000; 232: 225-232. doi: 10. 1097/00000658-200008000-00013.
5. Whooley BP, Law S, Murthy SC et al. Analysis of reduced death and complication rates after esophageal resection. Ann Surg. 2001; 233: 338-344. doi: 10. 1097/00000658-200103000-00006.
6. Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am. 2002; 82: 729-746. doi: 10. 1016/S0039-6109(02)00029-4.
7. Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007; 8: 226-234. doi: 10. 1016/S1470-2045(07)70039-6.
8. Greer SE, Goodney PP, Sutton JE et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005; 137: 172-177. doi: 10. 1016/j. surg. 2004. 06. 033.
9. Zacherl J, Sendler A, Stein HJ et al. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg. 2003; 27: 1067-1074.
10. Brucher BL, Stein HJ, Zimmermann F et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004; 30: 963-971.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70. doi: 10. 1016/S0092-8674(00)81683-9.
12. Yacoub L, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod Pathol. 1997; 10: 105-112.
13. Inada S, Koto T, Futami K et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999; 29: 493-503. doi: 10. 1007/BF02482343.
14. Wilkinson NW, Black JD, Roukhadze E et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg. 2004; 8: 448-453. doi: 10. 1016/j. gassur. 2004. 01. 006.
15. Gibault L, Metges JP, Conan-Charlet V et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005; 93: 107-115. doi: 10. 1038/sj. bjc. 6602625.
16. Safran H, Suntharalingam M, Dipetrillo T et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008; 70: 391-395. doi: 10. 1016/j. ijrobp. 2007. 07. 2325.
17. Polkowski W, van Sandick JW, Offerhaus GJ et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 1999; 6: 290-297. doi: 10. 1007/s10434-999-0290-2.
18. Brien TP, Odze RD, Sheehan CE et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol. 2000; 31: 35-39. doi: 10. 1016/S0046-8177(00)80195-1.
19. Aloia TA, Harpole DH Jr, Reed CE et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg. 2001; 72: 859-866. doi: 10. 1016/S0003-4975(01)02838-7.
20. Miyazono F, Metzger R, Warnecke-Eberz U et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer. 2004; 91: 666-672.
21. Akamatsu M, Matsumoto T, Oka K et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003; 57: 1323-1327. doi: 10. 1016/S0360-3016(03)00782-X.
22. Kuwahara M, Hirai T, Yoshida K et al. p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer. Dis Esophagus. 1999; 12: 116-119. doi: 10. 1046/j. 1442-2050. 1999. 00034. x.
23. Itami A, Shimada Y, Watanabe G, Imamura M. Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology. 1999; 57: 311-317. doi: 10. 1159/000012067.
24. Ikeda G, Isaji S, Chandra B et al. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer. 1999; 86: 1396-1405. doi: 10. 1002/(SICI)1097-0142(19991015)86: 8< 1396:: AID-CNCR3> 3. 0. CO; 2-H.
25. Sturm I, Petrowsky H, Volz R et al. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol. 2001; 19: 2272-2281.
26. Brock MV, Gou M, Akiyama Y et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003; 9: 2912-2919.
27. Shimada Y, Watanabe G, Yamasaki S et al. Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Eur J Cancer. 2000; 36: 987-993. doi: 10. 1016/S0959-8049(00)00049-6.
28. Nakashima S, Natsugoe S, Matsumoto M et al. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res. 2000; 20: 1933-1937.
29. Sohda M, Ishikawa H, Masuda N et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer. 2004; 110: 838-844. doi: 10. 1002/ijc. 20215.
30. Takayama T, Nagao M, Sawada H et al. Bcl-X expression in esophageal squamous cell carcinoma: association with tumor progression and prognosis. J Surg Oncol. 2001; 78: 116-123. doi: 10. 1002/jso. 1130.
31. Raouf AA, Evoy DA, Carton E et al. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus. 2003; 16: 17-23. doi: 10. 1046/j. 1442-2050. 2003. 00281. x.
32. Ikeguchi M, Maeta M, Kaibara N. Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer. Int J Mol Med. 2001; 7: 413-417.
33. Kato J, Kuwabara Y, Mitani M et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001; 95: 92-95. doi: 10. 1002/1097-0215(20010320)95: 2< 92:: AID-IJC1016> 3. 0. CO; 2-9.
34. Vallböhmer D, Kuhn E, Warnecke-Eberz U et al. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics. 2008; 9: 681-690. doi: 10. 2217/14622416. 9. 6. 681.
35. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer. 1998; 83: 652-659. doi: 10. 1002/(SICI)1097-0142(19980815)83: 4< 652:: AID-CNCR4> 3. 0. CO; 2-M.
36. Lord RVN, Salonga D, Danenberg KD et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000; 4: 135-142. doi: 10. 1016/S1091-255X(00)80049-9.
37. Vallböhmer D, Peters JH, Kuramochi H, Oh D, Yang D, Shimizu D, DeMeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, Danenberg PV, DeMeester TR. Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch Surg. 2006; 141: 476-481. doi: 10. 1001/archsurg. 141. 5. 476.
38. Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol. 2004; 87: 95-104. doi: 10. 1002/jso. 20070.
39. Kuo KT, Chow KC, Wu YC. Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann Thorac Surg. 2003; 76: 909-914. doi: 10. 1016/S0003-4975(03)00717-3.
40. Takatori H, Natsugoe S, Okumura H et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2008; 34: 397-402. doi: 10. 1016/j. ejso. 2007. 04. 011.
41. Han B, Liu J, Ma MJ, Zhao L. Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer. World J Gastroenterol. 2005; 11: 2188-2192.
42. Barclay C, Li AW, Geldenhuys L et al. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res. 2005; 11: 7683-7691. doi: 10. 1158/1078-0432. CCR-05-0771.
43. Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann EH, Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg. 2002; 21: 657-663. doi: 10. 1016/S1010-7940(02)00044-1.
44. Shimada H, Hoshino T, Okazumi S et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer. 2002; 86: 552-557. doi: 10. 1038/sj. bjc. 6600129.
45. Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg. 2004; 127: 1579-1586. doi: 10. 1016/j. jtcvs. 2003. 12. 034.
46. Xi H, Baldus SE, Warnecke-Eberz U et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res. 2005; 11: 8341-8347. doi: 10. 1158/1078-0432. CCR-04-2373.
47. Krishnadath KK, Tilanus HW, van BM et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol. 1997; 182: 331-338. doi: 10. 1002/(SICI)1096-9896(199707)182: 3< 331:: AID-PATH860> 3. 0. CO; 2-D.
48. Murray GI, Duncan ME, O'Neil P et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 1998; 185: 256-261. doi: 10. 1002/(SICI)1096-9896(199807)185: 3< 256:: AID-PATH115> 3. 0. CO; 2-A.
49. Sharma R, Chattopadhyay TK, Mathur M, Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology. 2004; 67: 300-309. doi: 10. 1159/000081331.
50. Tanioka Y, Yoshida T, Yagawa T et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 2003; 89: 2116-2121. doi: 10. 1038/sj. bjc. 6601372.